Neurocrine Biosciences to Acquire Diurnal for $2.5 Billion
Neurocrine Biosciences is reportedly nearing a deal to acquire Diurnal, a biotech company specializing in obesity disorder treatments, for over $2.5 billion. This acquisition would expand Neurocrine's portfolio in the rapidly growing obesity treatment market.